← Back to Clinical Trials
Recruiting Phase 2 NCT06244888

NCT06244888 Control Systems Engineering for Weight Loss Maintenance

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06244888
Status Recruiting
Phase Phase 2
Sponsor The Miriam Hospital
Condition Overweight and Obesity
Study Type INTERVENTIONAL
Enrollment 180 participants
Start Date 2024-02-26
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Intervention Targeting Stress and Emotion RegulationIntervention Targeting Motivation and Self-efficacy for Weight ManagementIntervention for Normalization of Eating

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 180 participants in total. It began in 2024-02-26 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This project capitalizes on principles of control systems engineering to build a dynamical model that predicts weight change during weight loss maintenance using behavioral, psychosocial, and environmental indicators evaluated in a system identification experiment. A 6-month behavioral obesity treatment will be administered to produce weight loss. Participants losing at least 3% of initial body weight will be followed for an additional 12 months via daily smartphone surveys that incorporates passive sensing to objectively monitor key behaviors. Survey data pertaining to behavioral, psychosocial, and environmental indicators will be used to develop a controller algorithm that can predict when an individual is entering a heightened period of risk for regain and why risk is elevated. Interventions targeting key risk indicators will be randomly administered during the system ID experiment. Survey and passive sensing data documenting the effects of the interventions will likewise drive development of the controller algorithm, allowing it to determine which interventions are most likely to counter risk of regain.

Eligibility Criteria

Inclusion Criteria: * English language fluent and literate at the 6th grade level * Body mass index (BMI) between 25 and 50 kg/m-squared * Able to walk 2 city blocks without stopping * Owns a smartphone Exclusion Criteria: * Report of a heart condition, chest pain during periods of activity or rest, or loss of consciousness in the 12 months prior to enrolling. * Currently participating in another weight loss program * Currently taking weight loss medication * Has lost ≥5% of body weight in the 6 months prior to enrolling * Has been pregnant within the 6 months prior to enrolling * Plans to become pregnant within 18 months of enrolling * Any medical condition that would affect the safety of participating in unsupervised physical activity * Any condition that would result in inability to follow the study protocol, including terminal illness and untreated major psychiatric illness

Contact & Investigator

Central Contact

Sharon O'Toole, M.A.T.

✉ sotoole@lifespan.org

📞 401 793-8992

Frequently Asked Questions

Who can join the NCT06244888 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Overweight and Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06244888 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT06244888 currently recruiting?

Yes, NCT06244888 is actively recruiting participants. Contact the research team at sotoole@lifespan.org for enrollment information.

Where is the NCT06244888 trial being conducted?

This trial is being conducted at Providence, United States.

Who is sponsoring the NCT06244888 clinical trial?

NCT06244888 is sponsored by The Miriam Hospital. The trial plans to enroll 180 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology